文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

单次低剂量人重组抗凝血酶(ATryn)对 endotoxin 诱导的弥散性血管内凝血无影响:一项实验性随机开放标签对照研究

Single Low Dose of Human Recombinant Antithrombin (ATryn) has no Impact on Endotoxin-Induced Disseminated Intravascular Coagulation: An Experimental Randomized Open Label Controlled Study.
PubMed 文献 · Shock · 2019-01-01
一句话结论在内毒素休克猪模型中,单次低剂量人重组抗凝血酶(100 U/kg,30分钟静脉输注)未预防DIC发生、严重程度、炎症反应或血流动力学改变。

该实验性随机开放标签对照研究以10头雌性Large White猪为对象,静脉输注大肠杆菌内毒素诱导休克后,随机分两组各5头,分别接受人重组抗凝血酶100 U/kg(30分钟静脉输注,ATryn组)或0.9%氯化钠(对照组),观察5小时。ATryn组抗凝血酶III活性从60分钟至300分钟均显著高于对照组。但重组人抗凝血酶补充对血流动力学、微循环参数、凝血参数(血小板计数、纤维蛋白原、凝血酶-抗凝血酶复合物、血管性血友病因子)的序贯变化均无影响,两组白细胞介素6和肿瘤坏死因子α水平全程统计学相同,肾小球血栓比例和肾小球内毛细血管血栓比例两组无显著差异。作者结论认为,在该内毒素休克模型中,单次低剂量重组人抗凝血酶未预防DIC发生、严重程度、炎症特征或血流动力学改变。

要点

  • 内毒素休克猪模型中,ATryn组抗凝血酶III活性在60分钟(213% [203-223] vs 104% [98-115],P=0.008)至300分钟(115% [95-124] vs 79% [67-93],P=0.03)均显著高于对照组。
  • 重组人抗凝血酶100 U/kg(30分钟静脉输注)对血流动力学和微循环参数无影响。
  • 重组人抗凝血酶对凝血参数(血小板计数、纤维蛋白原、凝血酶-抗凝血酶复合物、血管性血友病因子)的序贯变化无影响。
  • 两组白细胞介素6和肿瘤坏死因子α水平全程统计学相同,肾小球血栓及肾小球毛细血管血栓比例无显著差异。
  • 作者结论:在该内毒素休克模型中,单次低剂量重组人抗凝血酶未预防DIC发生、严重程度、炎症特征或血流动力学改变。

适用人群与场景

  • 雌性Large White猪,静脉输注大肠杆菌内毒素诱导内毒素休克模型,共10头,随机分两组各5头。

处置流程与药物剂量

  • ATryn组:人重组抗凝血酶100 U/kg,30分钟静脉输注,单次给药。
  • 对照组:0.9%氯化钠静脉输注。
  • 观察指标:抗凝血酶III水平、凝血、止血、炎症参数、血流动力学和微循环参数,观察5小时;安乐死后取肾脏行组织学评估。

研究设计与关键结果

  • 实验性随机开放标签对照研究,10头雌性Large White猪,随机分两组各5头,ATryn组接受人重组抗凝血酶100 U/kg(30分钟静脉输注),对照组接受0.9%氯化钠。
  • 抗凝血酶III活性ATryn组显著高于对照组:60分钟时为213% [203-223] vs 104% [98-115],P=0.008;300分钟时为115% [95-124] vs 79% [67-93],P=0.03。
  • 重组人抗凝血酶补充对血流动力学、微循环参数及凝血参数(血小板计数、纤维蛋白原、凝血酶-抗凝血酶复合物、血管性血友病因子)的序贯变化无影响。
  • 白细胞介素6和肿瘤坏死因子α水平两组全程统计学相同。
  • 肾小球血栓比例和肾小球内毛细血管血栓比例两组无显著差异。

证据类型、等级与局限

  • 证据类型:实验性随机开放标签对照研究(动物实验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在该内毒素休克模型中,单次低剂量重组人抗凝血酶未预防DIC发生、严重程度、炎症特征或血流动力学改变。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Antithrombin (AT) III physiological levels are decreased during septic shock and supplementation therapy could therefore be beneficial.

OBJECTIVE: We hypothesized that the use of recombinant human AT could reduce disseminated intravascular coagulation (DIC) occurrence.

METHODS: We conducted a randomized open label controlled experimental study. Ten female "Large White" pigs were challenged with i.v. infusion of Escherichia coli endotoxin. Two groups of 5 pigs were randomly assigned to receive either recombinant human AT 100 U/kg over 30 min (ATryn group) or 0.9% saline (control group). AT III levels, coagulation, hemostasis, inflammation parameters, hemodynamics, and microcirculatory parameters were measured over a 5-h period. Immediately after euthanasia, kidneys were withdrawn for histology evaluation. Statistical analysis was performed with nonparametric tests and Dunn's test for multiple comparisons.

RESULTS: AT III activity was significantly higher in the ATryn group than in the control group from 60% (213% [203-223] vs. 104% [98-115], P = 0.008, respectively) to 300 min (115% [95-124] vs. 79% [67-93], P = 0.03). Recombinant human AT supplementation had no impact on hemodynamics, microcirculatory parameters, and sequential changes of coagulation parameters (platelet count, fibrinogen level, thrombin-AT complexes, and von Willebrand factor). Interleukin 6 and tumor necrosis factor α values were statistically the same for both groups throughout the study. Percentage of thrombosed glomeruli and percentage of thrombosed capillary in glomerulus were not significantly different between both groups.

CONCLUSIONS: In our model of endotoxic shock, a single low dose of recombinant human AT did not prevent DIC occurrence, severity, inflammatory profile, or hemodynamic alterations.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Duburcq T, Durand A, Tournoys A, et al. Single Low Dose of Human Recombinant Antithrombin (ATryn) has no Impact on Endotoxin-Induced Disseminated Intravascular Coagulation: An Experimental Randomized Open Label Controlled Study. Shock. 2019. PMID: 30325871. doi:10.1097/SHK.0000000000001274

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。